Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.7700 (-6.72%) ($7.7700 - $8.3300) on Wed. Oct. 21, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.79% (three month average) | RSI | 43 | Latest Price | $7.7700(-6.72%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -4.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -0.6% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(33%) XBI(33%) ARKK(32%) BLOK(31%) ACES(30%) | Factors Impacting HTBX price | HTBX will decline at least -3.395% in a week (0% probabilities). VXX(-19%) VIXM(-18%) UUP(-14%) XLU(-4%) XLP(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.395% (StdDev 6.79%) | Hourly BBV | -1.5 () | Intraday Trend | -5.1% | | | |
|
Inflection Point | Yes | Resistance Level | $8.76 | 5 Day Moving Average | $8.62(-9.86%) | 10 Day Moving Average | $8.8(-11.7%) | 20 Day Moving Average | $8.76(-11.3%) | To recent high | -63.2% | To recent low | 8.8% | Market Cap | $855m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |